(c) As per the available information, following are the prices for various strengths:—

| Strength | Price (Rs.) |
|---|---|
| one g. . . . . | 194.98 |
| 500 mg. . . . . | 97.64 |
| 250 mg. . . . . | 48.95 |

**Review of Medical Education and Services**

1320. SHRI KRISHNA KUMAR BIRLA: Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

(a) whether Government have reviewed the medical education in the country to know the extent to which the medical colleges are equipped and the syllabi is uptodate keeping pace with the advancement in medical science the worldover;

(b) if so, what is the outcome thereof;

(c) whether there is any proposal under Government's consideration to constitute a commission for medical education and medical services in the country;

(d) if so, what are the details thereof; and

(e) if the answer to part (c) above be in the negative whether Government would consider such a proposal?

THE MINISTER OF STATE OF THE MINISTRY OF HEALTH AND FAMILY WELFARE (SHRI RASHEED MASOOD): (a) to (e) The Medical Council of India which is statutorily charged with the responsibility of maintaining the standard of medical education in the country, has been reviewing and revising the Undergraduate and Postgraduate curriculum from time to time to meet the needs of the country, as well as for keeping pace with the advancement in medical sciences the worldover. At present a review has been undertaken by the Council, both of Undergraduate and Postgraduate curriculum. The Medical Education Review Committee whose report was placed before the Parliament on the 2nd May, 1986, had made a recommendation for the establishment of an autonomous Medical and Health Education Commission, which would be responsible for consideration, planning and implementation of various medical and health education programmes in all branches of health sciences, planning for the development of health manpower, allocation of funds and disbursement of grants to medical and health institutions etc.

**Recovery of arrears towards DPEA**

1321. SHRI S. MADHAVAN: Will the Minister of PETROLEUM AND CHEMICALS be pleased to state:

(a) whether Government have taken steps to recover arrears towards the Drug Price Equalisation Accounts;

(b) what are the names of the companies from which such claims are pending;

(c) what are the total amounts to be realised from those companies; and

(d) what are the reasons for delay in realising these arrears?

THE MINISTER OF PETROLEUM AND CHEMICALS (SHRI M. S. GURUPADASWAMY): (a) Yes, Sir.

(b) to (c) A statement giving the details is enclosed (*See* below).

(d) Representations by some companies, court interventions and non-furnishing of certain details by some companies etc. are the major reasons for delay in recovery. The process of recovery is, however, in progress in accordance with due process of law in all those cases where liabilities have been assessed.

**Statement**

| Sl. No. | Name of the Company | Tentative amount calculated for the period ending 31-12-83 after review (Rs. in lakhs) |
|---|---|---|
| | (a) *Supreme Court case* | |
| 1 | M/s. Cyanamid India Ltd. | 536.91 |
| 2 | M/s. Hoehchst India Ltd. | 2491.05 |
| 3 | M/s. John Wyeth India Ltd. and | 173.02 |
| | M/s. Geoffrey Manners Ltd. | 128.37 |
| 4 | M/s. Ethnor Limited | 10.19 |
| 5 | Franco Indian Pharmaceuticals Ltd. and M/s. Griffon Ltd. | 14.02 |
| 6 | M/s. Pfizer Ltd. | 87.61 |
| 7 | M/s. Anil Starch Products Ltd. | 11.61 |
| 8 | M/s. S.G. Pharmaceuticals | 205.36 |
| 9 | Tamilnadu Dadha Pharmaceuticals | 37.97 |

(b) *Details of tentative amounts assessed and recoverable under Para* 7(2) *of DPCO*, 1979

| Sl. No. | Name of the Company | Period involved | Tentative amount assessed (Rs. in lakhs) |
|---|---|---|---|
| 1 | 2 | 3 | 4 |
| | *RIFAMPICIN* | | |
| 1 | Biochem Pharmaceuticals | 3/79 to 3/84 | 34.28 |
| 2 | Lyka Labs. | 4/79 to 3/84 | 57.57 |
| 3 | Astra IDL Ltd. | 82-83 to 5/84 | 24.11 |
| 4 | Micro Labs. | 79-80 to 82-83 | 2.24 |
| 5 | Themis Chemicals Ltd. | 82-83 to 83-84 | 36.31 |
| 6 | Alembic Chem. Labs. | 81-82 to 83-84 | 38.73 |
| 7 | Bombay Drug House | 80-81 to 83-84 | 1.73 |

| 1 | 2 | 3 | 4 |
|---|---|---|---|
| 8 | Pharmed Pvt. Ltd. | 79-80 to 83-84 | 66.01 |
| 9 | Dolphin Labs. | 1979 to 1983 | 18.11 |
| 10 | Albert David Ltd. | 11/81 to 9/83 | 3.91 |
| 11 | Pharma & Chem. Ind. | 80-81 to 82-83 | 87.99 |
| 12 | Cadila Labs. P. Ltd. | 79-80 to 83-84 | 76.52 |
| 13 | Sarabhai Chemicals | 82-83 to 83-84 | 4.14 |
| 14 | Lupin Labs. | 8/80 to 3/84 | 215.89 |
| 15 | Ranbaxy Labs. | 4/79 to 6/84 | 36.23 |
| 16 | Wallace Pharmaceuticals | 4/82 to 2/84 | 2.82 |
| 17 | Ethico Drug & Chem. Mfg. Co. | 5/82 to 3/84 | 140.98 |
| 18 | M/s. Indian Drugs & Pharmaceuticals Ltd. | 12/80 to 1/86 | 2.18 |
| 19 | M/s. Hindustan Antibiotics Ltd. | 81-82 to 83-84 | 36.66 |
| | | | 886.41 |
| | *DIPYRIDAMOL* | | |
| 1 | German Remedies | 4/79 to 7/84 | 59.95 |
| | *GENTAMYCIN* | | |
| 1 | Fulford I. Ltd. | 79-80 to 2/84 | 194.62 |
| 2 | Biochem Pharma Ltd. | 79-80 to 3/84 | 33.88 |
| 3 | Lyka Labs. Ltd. | 7/79 to 3/84 | 17.47 |
| 4 | Nicholas Labs. | 73-80 to 3/84 | 53.03 |
| | | | 299.00 |
| | *SALBUTAMOL* | | |
| 1 | Khandelwal Ltd. | 79-80 to 81-82 | 0.15 |
| 2 | Biddle Sawyer P. Ltd. | 4/79 to 3/83 | 142.74 |
| | | | 142.89 |
| | *CLOFAZAMINE* | | |
| 1 | S.G. Pharmaceuticals | 4/79 to 3/84 | 5.01 |
| | *AMPICILLIN & AMOXYCILLIN* | | |
| 1 | Biochem Pharma Ltd. | 79/80 to 83-84 | 11.80 |
| | *OXYPHENYLBUTAZONE* | | |
| 1 | Tablets India Ltd. | 79/80 to 83-84 | 9.49 |

| | | | |
|---|---|---|---|
| | *METRONIDAZOLE* | | |
| 1 | Boots Co. Ltd. . . . . | 79/80 to 25-8-87 | 62.17 |
| 2 | Smith Stanistreet Pharmaceuticals Ltd . | 79/80 to 83-84 | 7.82 |
| 3 | KSDPL . . . . . | 79-80 to 83-84 | 5.5 |
| 4 | Khandelwal Labs. . . . . | 79-80 to 3/84 | 1.34 |
| 5 | M/s. IDPL . . . . . | 79-80 to 3/84 | 20.33 |
| | | | 77.81 |
| | *SULPHAMETHOXAZOLE* | | |
| 1 | M/s. Burroughs Wellcome . . . | 1979-80 to Feb. 84 | 441.27 |
| | *TRIMETHOPRIM* | | |
| 1 | M/s. German Remedies . . . | 2/82 to 5/86 | 8.25 |
| | *FLUCINOLONE ACETAMIDE* | | |
| 1 | M/s. Lyka Labs. . . . . | 1979-80 to 25th August, 1987 | 678.73 |
| | (c) *Amounts recovered in High Court cases* | | |
| 1 | Sarabhai M. Chemicals . . . | | |
| 2 | Glaxo | | 6635.00 |
| | (d) *Amounts due against overcharging* | | |
| 1 | M/s. Warner Hindustan Ltd. (Now Parke Davis) | | 106.36 |

**इंडियन एयरलाइंस में नियुक्तियों में अनियमितताएं**

1322. **डा० अबरार अहमद खान :** क्या **नागर विमानन** मंत्री यह बताने की कृपा करेंगे कि :

(क) क्या इंडियन एयरलाइन्स में 26 ट्रैफिक अधिकारियों को पदोन्नत किया गया है और क्या इन अधिकारियों की पदोन्नति से पूर्व न्यायालय ने इस संबंध में स्थगन आदेश दिया था ;

(ख) यदि हां, तो उक्त आदेश का पालन न किये जाने के क्या कारण हैं ; और

(ग) क्या ट्रैफिक सहायकों का चयन विमान परिचारिकाओं की भर्ती के लिए बनाए गए पैनल में से कर लिया गया है। हालांकि ट्रैफिक सहायकों की भर्ती के लिए अलग से विज्ञापन दिया गया था और उस प्रयोजन के लिए एक टेस्ट लिया गया था; यदि हां, तो इस प्रकार की अनियमितताओं के लिए उत्तरदायी प्राधिकारियों के विरुद्ध क्या कार्यवाही की गई है ?

**सूचना और प्रसारण मंत्री तथा संसदीय कार्य मंत्री श्री पी० उपेन्द्र) :** (क) पदोन्नति कोटा के अन्तर्गत 26 अधिकारियों की पदोन्नति की गई है। उनकी पदोन्नति के बारे में न्यायालय से कोई स्थगन आदेश प्राप्त नहीं हुआ था।

(ख) प्रश्न नहीं है।

(ग) जी, हां। दिसम्बर, 1989 में ग्राहक सेवा काउंटरों के पुनर्गठन का निर्णय लिया गया था। अनन्य रूप से विमान परिचारिकाओं के संवर्ग के द्वारा भरे जाने वाली यात्री सुविधा सहायकों की रिक्तियों को ध्यान में रखते हुए यह निर्णय लिया गया था। सेवा में पदोन्नति के लिए यातायात सहायकों के साथ यात्री सुविधा सहायकों के संवर्ग का विलय करने का निर्णय किया गया था। यात्री सुविधा सहायकों और यातायात सहायकों के चयन की भर्ती एक जैसी नहीं है। चूंकि यातायात सहायकों (यात्री